Avin Maroof
YOU?
Author Swipe
View article: Discordance between patient and physician global assessments of psoriatic arthritis activity: an observational study in 13 Arab countries
Discordance between patient and physician global assessments of psoriatic arthritis activity: an observational study in 13 Arab countries Open
View article: Iraqi Registry Data Proves Safety and Efficacy of switching to Adalimumab Biosimilar in Treating Rheumatoid Arthritis
Iraqi Registry Data Proves Safety and Efficacy of switching to Adalimumab Biosimilar in Treating Rheumatoid Arthritis Open
Background: Adalimumab is approved for Rheumatoid Arthritis (RA). In 2021, A biosimilar (ABP501;Amgevita®) was licensed in Iraq. The current study aimed to ensure safety and Efficacy of Amgevita in RA Patients in Iraq. Patients and Methods…
View article: Is the patient-perceived impact of psoriatic arthritis a global concept? An international study in 13 Arab countries (TACTIC study)
Is the patient-perceived impact of psoriatic arthritis a global concept? An international study in 13 Arab countries (TACTIC study) Open
View article: Safety of COVID-19 Vaccine in Patients with Rheumatic and Musculoskeletal Diseases
Safety of COVID-19 Vaccine in Patients with Rheumatic and Musculoskeletal Diseases Open
The "COVID-19" vaccination has a reassuring safety profile with no greater risk of adverse events in any specific illness or pharmacological therapy.
View article: Patient registry data on the efficacy and tolerability of adalimumab biosimilar in ankylosing spondylitis: A retrospective multicenter observational study
Patient registry data on the efficacy and tolerability of adalimumab biosimilar in ankylosing spondylitis: A retrospective multicenter observational study Open
BACKGROUND: Adalimumab, a tumor necrosis factor-α inhibitor, is an approved treatment for ankylosing spondylitis (AS). In Iraq, a biosimilar of adalimumab (ABP 501; Amgevita®) has been licensed for prescription since 2021. However, there h…
View article: POS1542 THE PSORIATIC ARTHRITIS IMPACT OF DISEASE (PSAID-12) QUESTIONNAIRE IS VALID IN ARABIC AND STRONGLY LINKED TO DISEASE ACTIVITY AND PATIENT-REPORTED OUTCOMES IN ARAB-SPEAKING COUNTRIES: AN ARLAR INITIATIVE
POS1542 THE PSORIATIC ARTHRITIS IMPACT OF DISEASE (PSAID-12) QUESTIONNAIRE IS VALID IN ARABIC AND STRONGLY LINKED TO DISEASE ACTIVITY AND PATIENT-REPORTED OUTCOMES IN ARAB-SPEAKING COUNTRIES: AN ARLAR INITIATIVE Open
View article: AB1148 PATIENT AND PHYSICIAN GLOBAL ASSESSMENT OF PSORIATIC ARTHRITIS APPEAR MORE IN AGREEMENT IN ARAB COUNTRIES THAN PREVIOUSLY REPORTED ELSEWHERE – AN INTERNATIONAL STUDY UNDER THE AEGIS OF ARLAR
AB1148 PATIENT AND PHYSICIAN GLOBAL ASSESSMENT OF PSORIATIC ARTHRITIS APPEAR MORE IN AGREEMENT IN ARAB COUNTRIES THAN PREVIOUSLY REPORTED ELSEWHERE – AN INTERNATIONAL STUDY UNDER THE AEGIS OF ARLAR Open
View article: Is the Patient-Perceived Impact of Psoriatic Arthritis a Global Concept? An International Study in 13 Arab Countries
Is the Patient-Perceived Impact of Psoriatic Arthritis a Global Concept? An International Study in 13 Arab Countries Open
View article: COVID-19 AMONG A SAMPLE OF IRAQI PATIENTS WITH RHEUMATIC DISEASES: A MULTICENTER STUDY
COVID-19 AMONG A SAMPLE OF IRAQI PATIENTS WITH RHEUMATIC DISEASES: A MULTICENTER STUDY Open
Background: There are scarce data on disease characteristics and severity of coronavirus 2019 (COVID-19) among Iraqi patients with rheumatic diseases (RDs).In this study, we aimed to report the disease characteristics and variables associa…
View article: THU0476 NEW PARADIGMS IN FIBROMYALGIA RESEARCH: INFLAMMATORY CELLS-TO-LIPOPROTEINS RATIOS AS PREDICTIVE AND DISCRIMINATOR MARKERS
THU0476 NEW PARADIGMS IN FIBROMYALGIA RESEARCH: INFLAMMATORY CELLS-TO-LIPOPROTEINS RATIOS AS PREDICTIVE AND DISCRIMINATOR MARKERS Open